
|Articles|November 4, 2011
compensation survey link
Psychiatric Compensation 2012 Is your compensation keeping pace with that of your fellow psychiatrists? We surveyed practicing psychiatrists all across the country about their compensation and overall health of their practices. See what they said, then join the conversation about how your practice is different.
Advertisement
Is your compensation keeping pace with that of your fellow psychiatrists? We surveyed practicing psychiatrists all across the country about their compensation and overall health of their practices. See what they said, then join the conversation about how your practice is different.
Advertisement
Related to this article

In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.

2R,6R-HNK reproduces ketamine’s rapid antidepressant profile in rodents without dissociation or abuse signals, and is now in four phase 2 trials.

Explore how clinicians subtype depression using severity, stressors, suicidality, sleep, and anxiety patterns to sharpen diagnosis, guide treatment, and build trust.

Learn more about the randomized, double-blind phase 2b study of naturally derived psilocybin in MDD, and more.

In 2 pivotal phase 3 studies, all 5 readers hit sensitivity and specificity targets for florquinitau F 18 tau PET, including in patients with early symptomatic Alzheimer disease.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Ketamine for Treatment-Resistant Depression: Practical Clinical Considerations
2
sNDA Submitted: Caplyta for the Treatment of Bipolar Mania
3
Real-World Lecanemab Outcomes in Alzheimer Disease, Reported at 3 Years
4
Mixed Results From Phase 3 Data for AR1001 in Alzheimer Disease
5



